Melatonin enhances sorafenib actions in human hepatocarcinoma cells by inhibiting mTORC1/p70S6K/HIF-1α and hypoxia-mediated mitophagy

The antiangiogenic effects of sustained sorafenib treatment in hepatocellular carcinoma (HCC) lead to the occurrence of hypoxia-mediated drug resistance resulting in low therapy efficiency and negative outcomes. Combined treatments with coadjuvant compounds to target the hypoxia-inducible factor-1α...

Descripción completa

Detalles Bibliográficos
Autores principales: Prieto-Domínguez, Néstor, Méndez-Blanco, Carolina, Carbajo-Pescador, Sara, Fondevila, Flavia, García-Palomo, Andrés, González-Gallego, Javier, Mauriz, José L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710933/
https://www.ncbi.nlm.nih.gov/pubmed/29207653
http://dx.doi.org/10.18632/oncotarget.20592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710933/
https://www.ncbi.nlm.nih.gov/pubmed/29207653
http://dx.doi.org/10.18632/oncotarget.20592

Ejemplares similares